Sort
48,018 grants matching “immunotherapy”
Blocking the binding of Aβ and apoE as a novel therapeutic approach for AD
$514,519Thomas M Wisniewski · New York University School Of Medicine · P01 · FY2023 · AG
Function of Wdfy4 in cross-presentation and immunity
$514,458Kenneth M. Murphy · Washington University · R01 · FY2020 · AI
Blocking the binding of Aβ and apoE as a novel therapeutic approach for AD
$514,446Thomas M Wisniewski · New York University School Of Medicine · P01 · FY2024 · AG
Endothelial cells regulate immune reconstitution after hematopoietic stem cell transplantation
$514,445Marcel R M Van Den Brink · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
Targeting the Epigenome for Lung Cancer Therapy
$514,430David Schrump · Division Of Clinical Sciences - Nci · ZIA · FY2011 · CA
Epigenetic Mechanisms of Gene Expression in Lung Cancer Cells
$514,430David Schrump · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells
$514,429John H Sampson · Duke University · R01 · FY2015 · CA
Vaccines, Immunoprophylaxis, and Immunotherapy for SARS
$514,399Kanta Subbarao · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Modulation of Inflammatory Responses by Helminth Glycans
$514,349Richard D Cummings · Beth Israel Deaconess Medical Center · R01 · FY2015 · AI
Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes
$514,343Lawrence P Kane · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA
Cyclin Dependent Kinases as Epigenetic Therapy Targets
$514,307Jean-Pierre J Issa · Coriell Institute For Medical Research · P50 · FY2024 · CA
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis
$514,305Weizhou Zhang · University Of Florida · R01 · FY2025 · CA
Development of selective HDAC6 inhibitors to improve cancer immunotherapy
$514,297Alejandro V Villagra · Georgetown University · R01 · FY2022 · CA
Project 1: Blood Immunomethylomic Markers of Outcome in Glioblastoma Patients
$514,271John K. Wiencke · University Of California, San Francisco · P50 · FY2022 · CA
Project 1: Blood Immunomethylomic Markers of Outcome in Glioblastoma Patients
$514,270John K. Wiencke · University Of California, San Francisco · P50 · FY2021 · CA
Macrophage-specific nanotherapy for breast cancer
$514,198Bryan Ronain Smith · Michigan State University · R01 · FY2020 · CA
Defining Mechanisms of Progression and Treatment Resistance in Localized Bladder Cancer
$514,185Eugene Pietzak · Sloan-Kettering Inst Can Research · R37 · FY2025 · CA
Defining Mechanisms of Progression and Treatment Resistance in Localized Bladder Cancer
$514,185Eugene Pietzak · Sloan-Kettering Inst Can Research · R37 · FY2023 · CA
Impact of ART on DC and Teg Responses in Oral Tissues
$514,174Melissa J Robbiani · Population Council · R01 · FY2007 · DE
Effector T Cell Trafficking in Ovarian Cancer
$513,972Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2017 · CA
Effector T Cell Trafficking in Ovarian Cancer
$513,972Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2016 · CA
Biology and Therapy of Lymphopenia
$513,935Crystal Mackall · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Investigational Cancer Therapeutics Training Program
$513,912Dean F. Bajorin · Sloan-Kettering Inst Can Research · T32 · FY2019 · CA
Harnessing naturally occurring cell type-specific regulatory elements and normal HSC hematopoiesis to develop cell lineage-controlled CAR expression and continuously renewing CAR NK cells
$513,859Eric L Smith · Dana-Farber Cancer Inst · R01 · FY2025 · CA
Harnessing naturally occurring cell type-specific regulatory elements and normal HSC hematopoiesis to develop cell lineage-controlled CAR expression and continuously renewing CAR NK cells
$513,859Eric L Smith · Dana-Farber Cancer Inst · R01 · FY2024 · CA